ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -137,570 | 28,242 | 16,121 | 13,993 |
| Stock-based compensation | 16,670 | 19,371 | 19,087 | 44,279 |
| Depreciation and amortization | 6,368 | 6,390 | 6,386 | 17,542 |
| Accretion of available-for-sale securities premiums/discounts | 1,300 | 1,215 | 1,244 | 4,545 |
| Non-cash gain on treasury stock received | NaN | NaN | 3,193 | NaN |
| Amortization of convertible notes issuance costs | 657 | NaN | NaN | NaN |
| Realized gain on investments | 0 | 19 | 0 | 0 |
| Non-cash interest expense on liability related to the sale of future royalties | 8,832 | 7,600 | 7,143 | 18,893 |
| Non-cash interest expense on credit facility | 14,357 | 14,905 | 14,551 | 48,774 |
| Loss on equity method investment | -6,719 | NaN | NaN | NaN |
| Gain on vie's sale of ipr&d assets | 19,000 | NaN | NaN | NaN |
| Non-cash transfer of property and equipment to affiliate | 555 | NaN | NaN | NaN |
| Accounts receivable | -203,185 | 212,046 | 47,126 | 9,841 |
| Inventory | NaN | 451 | NaN | NaN |
| Prepaid expenses and other current assets | -4,769 | 13,182 | -12,403 | 22,342 |
| Accounts payable | -2,190 | 15,263 | -15,376 | 21,662 |
| Accrued expenses | -8,635 | -13,501 | 33,541 | 7,956 |
| Deferred revenue | -8,599 | 163,359 | -20,580 | 22,979 |
| Operating lease, net | -1,212 | -1,211 | -1,188 | -3,417 |
| Other | -385 | 24 | 34 | -3,128 |
| Net cash provided by operating activities | 84,442 | 13,481 | 20,491 | 159,061 |
| Purchases of investments | NaN | 136,933 | 21,642 | 774,616 |
| Proceeds from sales and maturities of investments | NaN | 115,339 | 101,750 | 587,880 |
| Purchases of property, plant and equipment | 2,565 | 2,148 | 7,489 | 15,177 |
| Purchases of available-for-sale securities | 1,061,577 | NaN | NaN | NaN |
| Proceeds from sales of available-for-sale securities | 23,748 | NaN | NaN | NaN |
| Proceeds from maturities of available-for-sale securities | 124,518 | NaN | NaN | NaN |
| Net cash used in investing activities | -894,282 | -23,742 | 72,619 | -201,913 |
| Repayments of credit facility | NaN | NaN | NaN | 201,625 |
| Proceeds from the exercises of stock options | 5,048 | 5,098 | 507 | 3,476 |
| Proceeds from visirna credit agreement | NaN | NaN | 3,162 | 7,098 |
| Proceeds from the sale of future royalties | NaN | NaN | 0 | 0 |
| Proceeds from issuance of warrants | 99,998 | 0 | 0 | 25,000 |
| Proceeds from the issuance of common stock, net of issuance costs paid | NaN | 46,832 | 0 | 241,388 |
| Proceeds from issuance of convertible notes | 700,000 | NaN | NaN | NaN |
| Payments of debt issuance costs | 18,716 | 0 | 0 | 5,000 |
| Purchase of capped calls | 47,880 | NaN | NaN | NaN |
| Proceeds from issuance of common stock-At The Market Agreement | 48,156 | NaN | NaN | NaN |
| Payments of issuance costs of common stock-At The Market Agreement | 1,324 | NaN | NaN | NaN |
| Proceeds from issuance of common stock-Underwriting Public Offering | 130,000 | NaN | NaN | NaN |
| Proceeds from credit facility | NaN | NaN | 0 | NaN |
| Payments of issuance costs of common stock-Underwriting Public Offering | 13,393 | NaN | NaN | NaN |
| Repayments of credit facility | 17,826 | 66,680 | 201,625 | NaN |
| Dividends paid by variable interest entity to noncontrolling shareholders | 41,514 | NaN | NaN | NaN |
| Net cash provided by financing activities | 795,717 | -14,750 | 3,669 | 70,337 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -14,123 | -25,011 | 96,779 | 27,485 |
| Effect of exchange rate changes on cash | NaN | 106 | -401 | NaN |
| Beginning of period | 24,905 | 226,548 | 102,685 | NaN |
| End of period | -13,126 | 201,643 | 226,548 | NaN |